Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-04-07
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotechnology company using its Recursion OS platform to discover and advance internal and partnered medicines across multiple therapeutic areas.
ai biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof unlocks the next rerating
The integrated lab-plus-data engine is real, but the equity story still turns on whether that engine can repeatedly create clinically valuable assets. If proof arrives, the current cash-adjusted valuation leaves room for a meaningful rerating; if not, dilution dominates.

Analysis

Thesis
At today’s cash-adjusted EV, the market is mostly paying for proof. If Recursion turns REC-4881 into a credible registrational path and shows one more repeatable platform-derived clinical asset, it can graduate from lumpy collaboration revenue to a multi-engine model spanning product sales, milestones, royalties, and externally financed asset vehicles.
Last Economy Alignment
Cheaper cognition helps because Recursion owns data, labs, and drug assets rather than seat software, but clinical proof and regulators still decide how much of that productivity it captures.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.9x (from 5 most recent analyses)
Reasoning
The upside case is a quality shift, not just a volume shift. If Recursion proves one registrational path and at least one additional repeatable clinical success, investors can value it as a platform that reliably mints assets and partner economics, not as a single-asset speculation. That supports a meaningfully larger business with a better quality multiple, though still below software-style premiums because approval risk, dilution, and long development cycles remain real.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The key risks are still proof and permissioning. If REC-4881 fails to secure a workable FDA path, REC-1245 does not validate repeatability, or partner monetization stays lumpy, the business can drift into a long period where dilution matters more than platform promise. The upside is meaningful because liquidity is solid and the integrated data-plus-lab stack is real, but clinical translation still decides whether Recursion earns premium economics or gets valued like outsourced discovery.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.56
They control proprietary biology data, automated labs, and an internal drug pipeline, so cheaper AI makes their machine more productive rather than replacing it. The risk is simple: if those tools do not keep turning into real clinical wins, big pharma can copy enough of the workflow and the market will stop paying a platform premium.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.20
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case